StrongBox Wealth LLC Sells 2,910 Shares of Zoetis Inc. (NYSE:ZTS)

StrongBox Wealth LLC trimmed its stake in Zoetis Inc. (NYSE:ZTS - Free Report) by 42.6% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 3,928 shares of the company's stock after selling 2,910 shares during the quarter. StrongBox Wealth LLC's holdings in Zoetis were worth $640,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently modified their holdings of the stock. Darwin Wealth Management LLC purchased a new stake in shares of Zoetis in the 3rd quarter valued at approximately $31,000. First Personal Financial Services acquired a new stake in Zoetis during the 3rd quarter valued at $33,000. Capital Performance Advisors LLP purchased a new stake in shares of Zoetis in the third quarter valued at $33,000. Dunhill Financial LLC lifted its holdings in shares of Zoetis by 80.6% in the third quarter. Dunhill Financial LLC now owns 168 shares of the company's stock valued at $33,000 after purchasing an additional 75 shares in the last quarter. Finally, Quarry LP boosted its position in shares of Zoetis by 273.2% in the second quarter. Quarry LP now owns 209 shares of the company's stock worth $36,000 after buying an additional 153 shares during the period. 92.80% of the stock is owned by institutional investors and hedge funds.

Zoetis Stock Up 1.3 %

Shares of ZTS traded up $2.13 during mid-day trading on Thursday, hitting $169.30. 2,804,357 shares of the company's stock were exchanged, compared to its average volume of 2,690,106. The company has a quick ratio of 2.27, a current ratio of 3.69 and a debt-to-equity ratio of 1.26. Zoetis Inc. has a twelve month low of $144.80 and a twelve month high of $200.53. The firm has a fifty day moving average of $171.25 and a two-hundred day moving average of $180.07. The stock has a market cap of $76.38 billion, a price-to-earnings ratio of 31.82, a P/E/G ratio of 2.51 and a beta of 0.89.

Zoetis (NYSE:ZTS - Get Free Report) last posted its earnings results on Monday, November 4th. The company reported $1.58 EPS for the quarter, topping the consensus estimate of $1.46 by $0.12. Zoetis had a net margin of 26.55% and a return on equity of 51.98%. The firm had revenue of $2.40 billion for the quarter, compared to the consensus estimate of $2.29 billion. During the same period in the prior year, the business posted $1.36 earnings per share. The business's quarterly revenue was up 11.6% on a year-over-year basis. On average, sell-side analysts forecast that Zoetis Inc. will post 5.91 earnings per share for the current year.

Zoetis Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, March 4th. Investors of record on Tuesday, January 21st will be issued a $0.50 dividend. This is a positive change from Zoetis's previous quarterly dividend of $0.43. This represents a $2.00 annualized dividend and a yield of 1.18%. The ex-dividend date is Tuesday, January 21st. Zoetis's payout ratio is 32.52%.

Wall Street Analyst Weigh In

ZTS has been the topic of several recent analyst reports. Leerink Partners assumed coverage on Zoetis in a research report on Monday, December 2nd. They set an "outperform" rating and a $215.00 price target on the stock. UBS Group assumed coverage on Zoetis in a report on Monday, December 9th. They issued a "neutral" rating and a $196.00 target price on the stock. JPMorgan Chase & Co. increased their price target on shares of Zoetis from $225.00 to $230.00 and gave the stock an "overweight" rating in a research report on Friday, October 11th. Leerink Partnrs raised shares of Zoetis to a "strong-buy" rating in a research report on Monday, December 2nd. Finally, Stifel Nicolaus dropped their price objective on shares of Zoetis from $210.00 to $180.00 and set a "buy" rating on the stock in a research note on Tuesday, January 7th. One analyst has rated the stock with a hold rating, nine have issued a buy rating and two have given a strong buy rating to the company's stock. Based on data from MarketBeat, the company currently has a consensus rating of "Buy" and an average price target of $211.89.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.